Press Release

Filament Health To Host Virtual Investor Update

May 8, 2023

Attendees will gain insight into the Company's drug development strategy, growing partnership network, and clinical trials

Vancouver, British Columbia, May 8, 2023  Filament HealthCorp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it will host a virtual update for investors and shareholders on Thursday, May 18, 2023 at 2:00 p.m. Eastern (11:00 a.m.Pacific).

During the event, Chief Executive Officer (CEO) Benjamin Lightburn and Chief Science Officer (CSO) Ryan Moss will discuss Filament’s recent progress including including US FDA approval of a clinical trial at theUniversity of California San Francisco and the manufacture of GMP MDMA, as well as plans for continued growth.

The presentation will be followed by a question-and-answer session with the Company’s senior management team.

WHO:             Benjamin Lightburn, CEO, and RyanMoss, CSO

WHEN:           Thursday, May 18, 2023 at 2:00 p.m.Eastern (11:00 a.m. Pacific)

WHERE:         RSVP to to receive access details.

A recording of the webcast will be available on the investor section of the Company’s website following the event.


Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at and on Twitter, Instagram and LinkedIn.


Anna Cordon, Director of Communications




Certain statements and information contained herein may constitute “forward-looking statements”and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”,“estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”,“guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the impact of the patent on the Company’s business and the ability of the Company to secure future patents. Forward-looking statements regarding theCompany are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws